

1222 • 2022  
**800**  
ANNI




UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA

# Cardiomiopatia Aritmogena

MASTER

Tecniche di acquisizione di risonanza magnetica cardiaca

AA 25\_26



## Secondary Cardiomyopathies

### Infiltrative\*

Amyloidosis (primary, familial autosomal dominant†, senile, secondary forms)

Gaucher disease‡

Hurler's disease‡

Hunter's disease‡

### Storage‡

Hemochromatosis

Fabry's disease‡

Glycogen storage disease‡ (type II, Pompe)

Niemann-Pick disease‡

### Toxicity

Drugs, heavy metals, chemical agents

### Endomyocardial







Endomyocardial fibrosis

Hypereosinophilic syndrome (Löeffler's endocarditis)

### Inflammatory (granulomatous)

Sarcoidosis


# Arrhythmogenic RV Cardiomyopathy



## Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia



### Proposed Modification of the Task Force Criteria

- I. Global or regional dysfunction & structural alterations
- II. Tissue characterization of wall
- III. Repolarization abnormalities
- IV. Depolarization/conduction abnormalities
- V. Arrhythmias
- VI. Family history



**RV goals-oriented!!!**

**Definite/Borderline/Possible Diagnosis**



«Triangle of dysplasia»



«Quadrangle of ARVC»  
which also includes the LV  
infero-lateral wall

Corrado D. Circulation Research. 2017 (784–802)

- Familial history of ARVC and/or sudden death
- ECG depolarization/conduction/repolarization abnormalities
- Arrhythmias of right ventricular origin
- **Global and/or regional dysfunction and structural alterations of the right ventricle**
- Fibro-fatty replacement of the right ventricular myocardium

McKenna et al, Br Heart J 1994



European Heart Journal (2010) **31**, 806–814  
doi:10.1093/eurheartj/ehq025

**SPECIAL REPORT**

# Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia

## Proposed Modification of the Task Force Criteria

Revision of the diagnostic criteria provides guidance on the role of emerging diagnostic modalities and advances in the genetics of ARVC/D. The criteria have been modified to incorporate new knowledge and technology to improve diagnostic sensitivity, but with the important requisite of maintaining diagnostic specificity. The approach of classifying structural, histological, electrocardiographic, arrhythmic, and genetic features of the disease as major and minor criteria has been maintained. In this modification of the Task Force criteria, quantitative criteria are proposed and abnormalities are defined on the basis of comparison with normal subject data.

# Global or regional dysfunction and structural alterations

## Major

### By 2D echo:

- Regional RV akinesia, dyskinesia, or aneurysm
- *and* 1 of the following (end diastole):
  - PLAX RVOT  $\geq 32$  mm (corrected for body size [PLAX/BSA]  $\geq 19$  mm/m<sup>2</sup>)
  - PSAX RVOT  $\geq 36$  mm (corrected for body size [PSAX/BSA]  $\geq 21$  mm/m<sup>2</sup>)
  - or fractional area change  $\leq 33\%$

### By MRI:

- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- *and* 1 of the following:
  - Ratio of RV end-diastolic volume to BSA  $\geq 110$  mL/m<sup>2</sup> (male) or  $\geq 100$  mL/m<sup>2</sup> (female)
  - or RV ejection fraction  $\leq 40\%$

### By RV angiography:

- Regional RV akinesia, dyskinesia, or aneurysm

# Global or regional dysfunction and structural alterations


## Minor

### By 2D echo:


- Regional RV akinesia or dyskinesia
- *and* 1 of the following (end diastole):
  - PLAX RVOT  $\geq 29$  to  $< 32$  mm (corrected for body size  $[PLAX/BSA] \geq 16$  to  $< 19$  mm/m<sup>2</sup>)
  - PSAX RVOT  $\geq 32$  to  $< 36$  mm (corrected for body size  $[PSAX/BSA] \geq 18$  to  $< 21$  mm/m<sup>2</sup>)
  - or fractional area change  $> 33\%$  to  $\leq 40\%$

### By MRI:


- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- *and* 1 of the following:
  - Ratio of RV end diastolic volume to BSA  $\geq 100$  to  $< 110$  mL/m<sup>2</sup> (male) or  $\geq 90$  to  $< 100$  mL/m<sup>2</sup> (female)
  - or RV ejection fraction  $> 40\%$  to  $\leq 45\%$




Sequenza Transassiale




p2C



p2C




p4C



p4C



p2C




Sequenza Asse Corto


CMR pocket guide EACVI

## Funzione del Vdx

1. Sequenze pulsate **Cine SSFP** (imaging parallelo se necessario)
2. **Modulo cine trans-assiale** (dal diaframma alla biforcazione della polmonare) o **modulo cine Asse Corto** come per il VSin
  - Spessore fetta 6-8mm
  - Distanza tra le fette 0mm
3. Risoluzione temporale  $\leq 45\text{ms}$



Modulo trans-assiale



Modulo asse corto

Schulz-Menger et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:35

## Right ventricle ranges for adults aged 20–80 years

Women					Men					
	'Opposite'	Reference range	Mildly abnormal	Moderately abnormal	Severely abnormal	'Opposite'	Reference range	Mildly abnormal	Moderately abnormal	Severely abnormal
20–68 years										
EDV (mL)	<77	77–201	202–232	233–263	>263	<118	118–250	251–283	284–316	>316
EDV/BSA (mL/m <sup>2</sup> )	<48	48–112	113–128	129–144	>144	<61	61–121	122–136	137–151	>151
ESV (mL)	<24	24–84	85–99	100–114	>114	<41	41–117	118–136	137–155	>155
ESV/BSA (mL/m <sup>2</sup> ) <sup>b</sup>	<12	12–52	53–62	63–72	>72	<19	19–59	60–69	70–79	>79
EF (%)	>71	51–71	41–51	30–40	<30	>72	52–72	41–52	30–40	<30
Mass (g) <sup>b</sup>	<21	21–49	50–56	57–63	>63	<25	25–57	58–65	66–73	>73
Mass/BSA (g/m <sup>2</sup> ) <sup>b</sup>	<12	12–28	29–32	33–36	>36	<13	13–29	30–33	34–37	>37

Using the statistical method:

- **normal** range is defined as  $\pm 2$  SD from the mean,
- **mildly** abnormal from this cut-off to 3 SD,
- **moderately** abnormal from the mild cut-off to 4 SD
- **severe** being more than 4 SD from the population mean.
- The term '**Opposite**' refers to values that are outside the normal range but in the opposite direction of typical thought of as pathology, e.g. smaller LV end-diastolic volumes or supra-normal LVEF.

## Right ventricle ranges for adults aged 20–80 years

Women					Men					
	'Opposite'	Reference range	Mildly abnormal	Moderately abnormal	Severely abnormal	'Opposite'	Reference range	Mildly abnormal	Moderately abnormal	Severely abnormal
20–68 years										
EDV (mL)	<77	77–201	202–232	233–263	>263	<118	118–250	251–283	284–316	>316
EDV/BSA (mL/m <sup>2</sup> )	<48	48–112	113–128	129–144	>144	<61	61–121	122–136	137–151	>151
ESV (mL)	<24	24–84	85–99	100–114	>114	<41	41–117	118–136	137–155	>155
ESV/BSA (mL/m <sup>2</sup> ) <sup>b</sup>	<12	12–52	53–62	63–72	>72	<19	19–59	60–69	70–79	>79
EF (%)	>71	51–71	41–51	30–40	<30	>72	52–72	41–52	30–40	<30
Mass (g) <sup>b</sup>	<21	21–49	50–56	57–63	>63	<25	25–57	58–65	66–73	>73
Mass/BSA (g/m <sup>2</sup> ) <sup>b</sup>	<12	12–28	29–32	33–36	>36	<13	13–29	30–33	34–37	>37

### By MRI:

- Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
- and 1 of the following:
  - Ratio of RV end-diastolic volume to BSA  $\geq 110$  mL/m<sup>2</sup> (male) or  $\geq 100$  mL/m<sup>2</sup> (female)
  - or RV ejection fraction  $\leq 40\%$

Using the statis

- normal ran
- mildly abno
- moderately
- severe beir

➤ The term 'C  
thought of a

## Limiti


- Range molto ampio di età (20-80 aa);
- Esclusi i teenagers → problema ARVC;
- Non differenze in base all'etnia;
- Non presenti valori diversi per la popolazione degli atleti.

## Pregi

- Più semplice il confronto con i valori di riferimento;
- Uniformità e semplificazione del post-processing;
- Il «grading» offre maggiore vicinanza alla pratica clinica.

**Esempio:**  
**FA 26%**

## Echo Limitations



- Acoustic window;
- Complexity of right ventricular geometry;
- Correct volumes/function evaluation;
- No information on tissue characterization

**FA ≤ 33% (major)**  
**FA 33-40 mm (minor)**

## CMR Advantages


- Evaluation of RV volumes/function
- Evaluation of RV wall and wall motion abnormalities
- Evaluation of Fatty Infiltration;
- Evaluation of Fibrosis

Sequence	Imaging plane	Parameters	Comments
<p><i>Double inversion recovery TSE/FSE</i></p> <p>a) Axial: <b>with and without fat suppression</b></p> <p>b) short axis: without fat suppression</p>	<p>a) Axial: obtain ~6-8 images centered on the left/right ventricle</p> <p>b) Short axis: obtain ~6-8 images centered on the left ventricle</p>	<p>TR = 2 R-R intervals, TE = 5 msec (minimum-full) (GE), TE = 30 msec (Siemens) slice thickness = 5 mm, interslice gap = 5 mm, and field of view (FOV) = 28–34 cm. ETL 16-24</p>	<p>This sequence provides optimal tissue characterization of the RV free wall. Prescribe from the pulmonary artery to the diaphragm. Fat suppression improves reader confidence in diagnosis of RV fat infiltration.</p>
<p><i>SSFP Bright Blood Cine Images</i></p>	<p>Axial, Four chamber and Short Axis. RV 3 chamber (optional)</p>	<p>TR/TE minimum, flip angle = 45-70°, slice thickness = 8 mm, interslice gap = 2 mm. FOV = 36–40 cm, 16–20 views per segment. Parallel imaging n = 2 is desirable</p>	<p>Axial images are best to assess RV wall motion. RV quantitative analysis is performed on the short axis cine images.</p>
<b>GADOLINIUM IS ADMINISTERED</b>		<b>(usually 0.15 – 0.2 MMOL/KG)</b>	
<p><i>TI scout</i></p>	<p>Four chamber</p>		<p>TI scout sequences or trial TI times to suppress normal myocardium for the right inversion time.</p>
<p><i>Delayed Gadolinium Imaging (Phase Sensitive Inversion Recovery recommended)</i></p>	<p>Axial, Short Axis, Four Chamber and Vertical Long Axis</p>	<p>TR/TE per manufacturer recommendations flip angle = 20-25°, slice thickness = 8 mm, interslice gap = 2 mm. FOV = 36–40 cm, No parallel imaging. Use phase sensitive inversion recovery if available (PSIR)</p>	<p>PSIR is more robust and independent of TI time. Optimal for imaging fibrosis. LV epicardial enhancement in the infero-lateral wall has been reported in classic ARVC and in left dominant forms.</p>

**Abbreviations:** ARVC Arrhythmogenic Right Ventricular Cardiomyopathy, LV left ventricle, FOV field of view, FSE fast spin echo, PSIR phase sensitive inversion recovery, RV right ventricle, SSFP steady state free precession, TE echo time, TI inversion time, TR repetition time, TSE Turbo spin echo.

## CMR Advantages


- Evaluation of RV volumes/function
- Evaluation of RV wall and wall motion abnormalities
- Evaluation of Fatty Infiltration;
- Evaluation of Fibrosis




## CMR Advantages

- Evaluation of RV volumes/function
- Evaluation of RV wall and wall motion abnormalities
- Evaluation of Fatty Infiltration;
- Evaluation of Fibrosis

# Akinesia





**Abnormal systolic motion (opposite to normal myocardium)**




**An akinetic segment with abnormal profile and motion both during systole & diastole.**




## Guardare alla sede!!!





## Guardare alla sede!!!




## Guardare alla sede!!!



## RV Free Wall Tether




### RV Free Wall Tether



Nelle cine, la porzione «tethered» del VDX (parete libera) rimane nella stessa posizione, immobile, rispetto al resto del miocardio.



Si riesce a vedere la cosiddetta «Triangular-shaped RV» il cui aspetto rimane invariato in sistole.

## Pectus Excavatum




**“banana-  
shaped RV”**

## Apicolateral Bulge




## Apicolateral Bulge




At the insertion  
site of the  
moderator  
band in the  
apicolateral  
wall

## Apical Aneurysm

NORMAL




«BUTTERFLY APEX»



NORMAL



## Pulmonary Valve Sinuses



a.



b.




**ARVC**


## Pulmonary Valve Sinuses



a.




b.



## CMR Advantages

- Evaluation of RV volumes/function
- Evaluation of RV wall and wall motion abnormalities
- **Evaluation of Fatty Infiltration;**
- Evaluation of Fibrosis

- CMR originally attracted interest in ARVC owing to the ability of fast spin-echo images to differentiate between normal myocardium and fat.
- Initial results were impressive, with reports that T1-weighted spin echo images correctly identified myocardial fat, both in formalin-fixed hearts and in vivo




## MR Imaging of Arrhythmogenic Right Ventricular Cardiomyopathy: Morphologic Findings and Interobserver Reliability

Cardiology 2003;99:153–162

## Magnetic Resonance Imaging of Arrhythmogenic Right Ventricular Dysplasia




Sensitivity, Specificity, and Observer Variability of Fat Detection Versus Functional Analysis of the Right Ventricle




**Table 4.** Incidence and Interobserver Agreement for the Qualitative Magnetic Resonance Variables



Variable	ARVD	IVT	Controls	% Agreement	Kappa	z-Score	p Value
Intramyocardial fat	84%	34%	4%	88%	0.74	5.75	<0.001
Wall thinning	6%	0%	0%	100%	0.29	2.26	0.01
RV dilation	68%	4%	0%	95%	0.84	6.52	<0.001
Regional function	78%	0%	4%	97%	0.90	6.92	<0.001
RV outflow tract enlargement	66%	0%	4%	93%	0.78	5.13	<0.001

Fat infiltration of the RV had a sensitivity of 84% and specificity of 79% with a positive predictive value of 80%. Regional wall motion abnormality of the RV had a sensitivity of 75% and specificity of 97% with a positive predictive value of 90%.





***CICATRICE POST-INFARTUALE***



**ADIPOSITAS CORDIS**

1. Evaluation of fibrofatty infiltration only as a secondary assessment after the evaluation of the more reliable functional and structural assessment of the RV;
2. Compare with cine images

“ARVC is predominantly a genetically determined heart muscle disorder that is characterized pathologically by fibrofatty replacement of the right ventricular myocardium”

Marcus et al. EHJ 2010;31, 806–814

***Is there a chance for fibrosis detection by CMR?***

# Tissue characterization of wall modified Task Force 2010

## Major

- **Residual myocytes 60%** by morphometric analysis (or 50% if estimated), with **fibrous replacement** of the RV free wall myocardium in  $\geq 1$  sample, *with or without fatty replacement* of tissue on endomyocardial biopsy

## Minor


- Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in  $\geq 1$  sample, with or without fatty replacement of tissue on endomyocardial biopsy

## CMR Advantages

- Evaluation of RV volumes/function
- Evaluation of RV wall and wall motion abnormalities
- Evaluation of Fatty Infiltration;
- Evaluation of Fibrosis

# Noninvasive Detection of Myocardial Fibrosis in Arrhythmogenic Right Ventricular Cardiomyopathy Using Delayed-Enhancement Magnetic Resonance Imaging

Tandri H et al J Am Coll Cardiol 2005;45:98 –103





**Eight (67%) of the 12 ARVC patients demonstrated LGE in the RV compared with none (0%) of the 18 patients without ARVC ( $p < 0.001$ ).**

**Table 2.** Correlation of MR Myocardial Delayed Enhancement With EP and Histologic Findings in ARVD Patients

Case	MR Imaging				EP Testing			Histopathology		
	Fat	Regional Function	MDE	Segments Abnormal	Arrhythmia Morphology	Site	Length (ms)	Fat	Fibrosis	Inflammation
1	ant/RVOT	ant-DK	ant	7	LBBB-SA	apex	260	+	+++	none
2	none	ant-DK	ant	4	RBBB-LA	apex	202	+	+++	none
3	ant/RVOT	ant-DK	diffuse	6	LBBB-IA	RVOT	240	+	+++	+
4	basal	normal	none	0	noninducible	—	—	none	none	none
5	basal	basal DK	basal	3	noninducible	—	—	ND	ND	ND
6	none	RVOT DK	none	0	not done	—	—	ND	ND	ND
7	none	normal	none	0	noninducible	—	—	none	none	none
8	ant/RVOT	basal DK	ant-basal	3	LBBB-IA, LBBB-RA	apex	240,232	none	none	none
9	none	normal	none	0	noninducible	—	—	none	none	+
10	none	ant-DK	ant-basal	1	not done	—	—	ND	ND	ND
11	ant/basal	ant-DK	ant/IVS*	8	LBBB-SA	RVOT	230	none	+	+++
12	ant/RVOT	ant-DK	ant	7	RBBB-LA	RVOT	300	+	+++	+

- **LGE correlated better than abnormal signal-averaged ECG (5 of 6) or RV dysfunction (4 of 6) in predicting VT on EP testing.**
- **None of the ARVD/C patients without delayed enhancement was inducible.**




- **The extent of fibrosis showed an inverse correlation with global RV function and a direct correlation with increased RV end-diastolic volume**

# ***LGE in ARVC: Controversies and Caveats***

- Selection bias-patient population studied (probands vs family members, different genotype, etc);
- Histological correlations;
- Look at LV;
- Differential diagnosis;
- Comparison with kinetics;
- A role in the Task Force Criteria: Padua Criteria

- **Endomyocardial biopsy was performed in 9 of the 12 patients who had the final diagnosis of ARVD/C.**
  - **4 (44%) fibro-fatty ARVD/C -> all LGE**
  - **1 (11%) myocarditis -> LGE**
  - **4 (44%) had normal biopsies -> only 1 had LGE**

**However a definitive histologic-proven basis of RV LGE in ARVC remains to be established**



Circulation. 1995;92:1117-1125




1222·2022  
**800**  
A N N I









UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA


# CARATTERIZZAZIONE TISSUTALE & RM:

## CASO 1















1222-2022  
**800**  
ANNI









UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA












1222·2022  
**800**  
A N N I




UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA








**A**



**B**




## CARDIOMIOPATIA ARITMOGENA «LEFT DOMINANT»



**Table 6** Clinical Diagnostic Features of LDAC\*

ECG	Unexplained T-wave inversion in $V_5$ , $V_6 \pm V_4$ , I, and aVL
Arrhythmia	Sustained or nonsustained ventricular tachycardia of RBBB configuration documented on ECG or Holter monitoring or during exercise testing Frequent ventricular extrasystoles (RBBB morphology)
Imaging	LV aneurysms Mild LV dilation and/or systolic impairment (with arrhythmic presentation)*
Biopsy/CMR	Myocyte loss with fibrofatty replacement on histology Extensive LGE of LV myocardium (with subepicardial/midmyocardial distribution)

# CMP a fenotipo «non dilatativo e non ipertrofico»





Il VS era coinvolto in più del 50% dei casi.



# Nuovo approccio alla Cardiomiopatia Aritmogena

Once upon a time.....



199

201



# Nuovo approccio alla Cardiomiopatia Aritmogena

Once upon a time.....

*Br Heart* 1994;71:215-218 215

---

CRITERIA

---


**Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy**

William J McKenna, Gaetano Thiene, Andrea Nava, Fabrice Fontalran, Carina Blomstrom-Lundqvist, Guy Fontaine, Fulvio Camerini on behalf of the Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology, supported by the Schoepfer Association.

**Special Report**

**Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia**  
**Proposed Modification of the Task Force Criteria**

Frank I. Marcus, MD, Chair; William J. McKenna, MD, DSc, Co-Chair; Duane Sherrill, PhD; Cristina Basso, MD, PhD; Barbara Bauce, MD; David A. Bluemke, MD, PhD; Hugh Calkins, MD; Domenico Corrado, MD, PhD; Moniek G.P.J. Cox, MD; James P. Daubert, MD; Guy Fontaine, MD, PhD; Kathleen Gear, RN; Richard Hauer, NW, MD; Andrea Nava, MD; Michael H. Picard, MD; Nikos Protonotarios, MD; Jeffrey E. Saffitz, MD, PhD; Danita M. Yoerger Sanborn, MD, MMSc; Jonathan S. Steinberg, MD; Harikrishna Tandri, MD; Gaetano Thiene, MD; Jeffrey A. Towbin, MD; Adalena Tsatsopoulou, MD; Thomas Wichter, MD; Wojciech Zareba, MD, PhD



Corrado D. *Circulation Research*. 2017 (784–802)

1994

2010

2023

**CMR &  
LGE**

## Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria

Check for updates

Domenico Corrado <sup>a,\*</sup>, Martina Perazzolo Marra <sup>a</sup>, Alessandro Zorzi <sup>a</sup>, Giorgia Beffagna <sup>a</sup>, Alberto Cipriani <sup>a</sup>, Manuel De Lazzari <sup>a</sup>, Federico Migliore <sup>a</sup>, Kalliopi Pilichou <sup>a</sup>, Alessandra Rampazzo <sup>b</sup>, Ilaria Rigato <sup>a</sup>, Stefania Rizzo <sup>a</sup>, Gaetano Thiene <sup>a</sup>, Aris Anastasakis <sup>c</sup>, Angeliki Asimaki <sup>d</sup>, Chiara Bucciarelli-Ducci <sup>e</sup>, Kristine H. Haugaa <sup>f</sup>, Francis E. Marchlinski <sup>g</sup>, Andrea Mazzanti <sup>h</sup>, William J. McKenna <sup>i</sup>, Antonis Pantazis <sup>j</sup>, Antonio Pelliccia <sup>k</sup>, Christian Schmied <sup>l</sup>, Sanjay Sharma <sup>m</sup>, Thomas Wichter <sup>n</sup>, Barbara Bauce <sup>a</sup>, Cristina Basso <sup>a</sup>



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA

# Nuovo approccio alla Cardiomiopatia Aritmogena



ESC

European Society  
of Cardiology


European Heart Journal (2019) 0, 1–16

doi:10.1093/eurheartj/ehz669


**CURRENT OPINION**

*Heart failure/cardiomyopathy*


## Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis



**ARVC= echo**



**AC= CMR**







# Nuovo approccio alla Cardiomiopatia Aritmogena

**CONCORDANZA CINE-LGE**


**CASO 2**



*Cine asse  
corto.*



*Asse corto post-  
contrasto.*



**SI PER VDX**

**NO PER VSN**




# Nuovo approccio alla Cardiomiopatia Aritmogena

CONTEMPORARY REVIEW

Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy

## Diagnostic flow-chart for ACM phenotypic variants



Corrado D et al. J Am Heart Assoc. 2021



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA



**ESC**

European Society  
of Cardiology

European Heart Journal (2022) **00**, 1–130  
<https://doi.org/10.1093/eurheartj/ehac262>

**ESC GUIDELINES**

---

# **2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death**

**Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC)**

**Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC)**



# ...nella cardiomiopatia aritmogena

ARVC is characterized by a predominant RV involvement. The 2010 revised international diagnostic task force criteria are based on a multiparametric strategy<sup>116</sup> (Figure 21). Tissue characterization by CMR was not included. However, RV fatty infiltration and LV LGE are frequently observed (in 29–53% and 35.5–45% of probands, respectively) and may be present before patients meet major task force imaging criteria.<sup>676–678</sup> Both wall motion alterations and pre-/post-contrast signal abnormalities have been suggested to enhance the diagnostic accuracy of CMR for ARVC.<sup>679</sup> The identification of biventricular and left-dominant involvement in ARVC patients<sup>680,681</sup> has recently led to the proposed term ‘arrhythmogenic cardiomyopathy’.<sup>682</sup>

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
<b>Diagnostic evaluation and general recommendations</b>		
In patients with suspected ARVC, CMR is recommended. <sup>676–678</sup>	<b>I</b>	<b>B</b>




UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA


**Ma allora se è LGE, che sia vero!!!**

## ➤ Interpretazione di LGE “giunzionale”







**Giunzione di un paziente con  
DCM**



**Giunzione di un soggetto  
normale**

Right Ventricular Junctional Late  
Gadolinium Enhancement Correlates With  
Outcomes in Pulmonary Hypertension

**FIGURE 1** Histological Basis of Junctional LGE in Nonischemic Dilated Cardiomyopathy




RESEARCH


Open Access



What is the mid-wall linear high intensity “lesion” on cardiovascular magnetic resonance late gadolinium enhancement?




## ➤ LGE settale




## RESEARCH

## Open Access




## ➤ LGE settale

What is the mid-wall linear high intensity “lesion” on cardiovascular magnetic resonance late gadolinium enhancement?



**Fig. 6** Forty-six-year-old, male, dilated cardiomyopathy. Typical mid-wall fibrosis is seen in the mid-layer of the basal septum from the anterior to the inferior side (**a**; arrow). The LGE pattern is distinctly different from that of the anterior septal perforator artery observed using CorCTA on another day (**b**; arrow)


- La diagnosi differenziale della forma ARVC
- La diagnosi differenziale della forma ALVC
- La diagnosi differenziale nelle forme dilatative



- La diagnosi differenziale della forma ARVC
- La diagnosi differenziale della forma ALVC
- La diagnosi differenziale nelle forme dilatative


## Clinical Key Points

- Phenocopies -> mimicking RV-dominant







- La diagnosi differenziale della forma ARVC
- **La diagnosi differenziale della forma ALVC**
- La diagnosi differenziale nelle forme dilatative

## Relationship Between Electrocardiographic Findings and Cardiac Magnetic Resonance Phenotypes in Arrhythmogenic Cardiomyopathy




# CMP a fenotipo «non dilatativo e non ipertrofico»





# CMP a fenotipo «non dilatativo e non ipertrofico»

## SARCOIDOSI

Blocco atrio-ventricolare avanzato, FA e TVNS sono comuni nella sarcoidosi.





## SARCOIDOSI




- fisiologia restrittiva del VS
- **granulomi miocardici** nelle immagini post-contrasto: **intramurali, a chiazze, prevalentemente laterale basale.** Rispondono alla terapia immunosoppressiva
- **LGE non secondo territorio di distribuzione coronarica**

# CMP a fenotipo «non dilatativo e non ipertrofico»



## SARCOIDOSI



# Myocardial Tissue Characterization in Arrhythmogenic Cardiomyopathy. Comparison Between Endomyocardial Biopsy and Cardiac Magnetic Resonance




# Myocardial Tissue Characterization in Arrhythmogenic Cardiomyopathy. Comparison Between Endomyocardial Biopsy and Cardiac Magnetic Resonance



# Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy

Corrado D et al. J Am Heart Assoc. 2021




## Basal Inferoseptal Triangular Late Gadolinium Enhancement

**FIGURE 1** Illustration of Septal and Inferoseptal Basal Triangular Scar Patterns in Cardiac Sarcoidosis


**A** Pattern A: Basal inferoseptal triangular LGE +/- endocardial RV septal LGE




Sarcoidosis



Lamin A cardiomyopathy




Sarcoidosis



Pattern B: Endocardial RV septal LGE




Giant Cell myocarditis




Pattern C: Mid-Septal LGE



Sarcoidosis









Idiopathic




## Clinical Key Points

- Phenocopies -> mimicking LV-dominant




- La diagnosi differenziale della forma ARVC
- La diagnosi differenziale della forma ALVC
- La diagnosi differenziale nelle forme dilatative

## Arrhythmogenic Right Ventricular Cardiomyopathy: Characterization of Left Ventricular Phenotype and Differential Diagnosis With Dilated Cardiomyopathy



Cipriani J Am Heart Assoc. 2020





# Come distinguo una DCM da una cardiomiopatia aritmogena LV-dominant?


	CLINICA	ECG	ARITMIE	CMR
<b>ALVC</b>	Gene-related? -Sincope	<ul style="list-style-type: none"><li>- Bassi voltaggi nelle derivazioni periferiche (&lt;0.5 mV)</li><li>- Onde T negative infero-laterali</li></ul>	TV monomorfa BBDx	<ul style="list-style-type: none"><li>- <b>LGE 100% dei casi</b></li><li>- Importante quantità di LGE (&gt;20%)</li><li>- Relazione diretta tra quantità di LGE e disfunzione sistolica</li><li>- LVLGE con pattern subepicardico/midmurale circolare &gt;&gt; infero-laterale laterale</li></ul>
<b>DCM</b>	Scompenso cardiaco; - Aritmie «gene-related»?	<ul style="list-style-type: none"><li>- IVS</li><li>- BBSX</li></ul>		<ul style="list-style-type: none"><li>- <b>LGE 40-45%</b></li><li>- Poca quantità LGE (&lt;10-15%)</li><li>- Disfunzione sistolica indipendente dalla quantità di LGE</li><li>- LV LGE &gt;&gt; SIV</li></ul>

## ➤ CARDIOMIOPATIE PRIMARIE


### ➤ ARVC

**J Cardiovasc Med 2017**

ARVC			
Cause of RV dilation or dysfunction	8	-	Cine-bSSFP in short-axis views from mitral valve to apex Q <sub>p</sub> /Q <sub>s</sub> evaluation with VEPC
Identification of biventricular tissue and wall motion abnormalities in patients with ventricular arrhythmias	7	-	Cine-bSSFP in short-axis and long-axis views FSE in short-axis and long-axis views LGE in short-axis and long-axis views
Follow-up CMR in patients with tissue abnormalities or wall motion abnormalities or RV dilatation, not satisfying TF criteria	7	-	As above
CMR in mutation carries or familiar of a ARVC proband	7	-	As above



## Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Non-Ischemic Cardiomyopathy



Patel, A.R. et al. J Am Coll Cardiol Img. 2017;10(10):1180-93.

**GRAZIE DELL'ATTENZIONE**

1222 • 2022  
**800**  
ANNI



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA